Insilico Medicine, a Chinese generative AI-driven biotech company, announced the completion of IND-enabling studies for its oral NLRP3 inhibitor, ISM8969. The company plans to submit an Investigational New Drug (IND) application in the fourth quarter of 2025.
Drug Development
ISM8969 was developed using Insilico’s Pharma.AI platform. It is an orally administered NLRP3 inhibitor capable of penetrating the blood-brain barrier. Preclinical IND-enabling studies demonstrated favorable pharmacokinetic/pharmacodynamic (PK/PD) profiles.
Therapeutic Potential
ISM8969 showed dose-dependent improvements in motor function in animal models. It has exhibited therapeutic potential for neurodegenerative diseases and is set to advance to clinical evaluation as a potential treatment for Parkinson’s disease (PD).-Fineline Info & Tech
